Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) — Tangible Net Worth Ratio
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has a Tangible Net Worth Ratio of 70.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥500.66 Million) from net assets (CN¥1.69 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Jiangsu Lianhuan Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Jiangsu Lianhuan Pharmaceutical Co Ltd Tangible Net Worth Ratio (2000–2024)
This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 25 annual periods from 2000 to 2024. As of March 2026, the ratio stands at 70.3%, reflecting net assets of CN¥1.69 Billion with intangible assets of CN¥500.66 Million CNY. For live market cap and overall valuation, see Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) market capitalisation.
Annual Tangible Net Worth Ratio for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024, covering 25 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore reinvestment intensity of Jiangsu Lianhuan Pharmaceutical Co Ltd to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 83.6% | CN¥1.58 Billion | CN¥258.77 Million | CN¥3.02 Billion | ▼ -7.2 pp |
| 2023 | 90.8% | CN¥1.52 Billion | CN¥138.97 Million | CN¥2.86 Billion | ▼ -0.2 pp |
| 2022 | 91.1% | CN¥1.41 Billion | CN¥126.19 Million | CN¥2.71 Billion | ▲ +0.4 pp |
| 2021 | 90.7% | CN¥1.28 Billion | CN¥118.89 Million | CN¥2.35 Billion | ▼ -0.6 pp |
| 2020 | 91.3% | CN¥1.18 Billion | CN¥102.57 Million | CN¥2.05 Billion | ▼ -0.3 pp |
| 2019 | 91.6% | CN¥1.08 Billion | CN¥91.10 Million | CN¥1.89 Billion | ▼ -3.2 pp |
| 2018 | 94.8% | CN¥946.61 Million | CN¥49.53 Million | CN¥1.42 Billion | ▲ +0.0 pp |
| 2017 | 94.7% | CN¥878.23 Million | CN¥46.23 Million | CN¥1.16 Billion | ▼ -0.1 pp |
| 2016 | 94.8% | CN¥827.25 Million | CN¥42.68 Million | CN¥1.07 Billion | ▼ -4.0 pp |
| 2015 | 98.8% | CN¥774.88 Million | CN¥9.05 Million | CN¥1.00 Billion | ▲ +0.0 pp |
| 2014 | 98.8% | CN¥434.25 Million | CN¥5.17 Million | CN¥658.96 Million | ▲ +0.4 pp |
| 2013 | 98.4% | CN¥402.11 Million | CN¥6.41 Million | CN¥649.48 Million | ▲ +0.2 pp |
| 2012 | 98.2% | CN¥350.42 Million | CN¥6.28 Million | CN¥443.21 Million | ▲ +0.5 pp |
| 2011 | 97.7% | CN¥327.61 Million | CN¥7.50 Million | CN¥418.52 Million | ▲ +0.9 pp |
| 2010 | 96.8% | CN¥308.95 Million | CN¥9.88 Million | CN¥401.08 Million | ▲ +0.9 pp |
| 2009 | 95.9% | CN¥293.89 Million | CN¥12.08 Million | CN¥383.36 Million | ▲ +1.0 pp |
| 2008 | 94.9% | CN¥281.68 Million | CN¥14.29 Million | CN¥359.66 Million | ▼ -3.5 pp |
| 2007 | 98.5% | CN¥269.97 Million | CN¥4.13 Million | CN¥357.66 Million | ▲ +0.4 pp |
| 2006 | 98.0% | CN¥259.20 Million | CN¥5.13 Million | CN¥335.84 Million | ▲ +0.4 pp |
| 2005 | 97.6% | CN¥255.97 Million | CN¥6.12 Million | CN¥305.41 Million | ▲ +0.4 pp |
| 2004 | 97.2% | CN¥250.42 Million | CN¥7.11 Million | CN¥312.05 Million | ▲ +0.5 pp |
| 2003 | 96.7% | CN¥246.22 Million | CN¥8.19 Million | CN¥293.21 Million | ▲ +7.3 pp |
| 2002 | 89.3% | CN¥85.26 Million | CN¥9.10 Million | CN¥126.28 Million | ▲ +3.8 pp |
| 2001 | 85.5% | CN¥69.48 Million | CN¥10.09 Million | CN¥115.66 Million | ▲ +4.8 pp |
| 2000 | 80.7% | CN¥55.16 Million | CN¥10.67 Million | CN¥103.67 Million | — |